% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • kyle.ramer kyle.ramer Jul 22, 2013 9:33 PM Flag

    Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

    I was able to view the full study it is quite lengthy and very impressive. If some of the boards people with a science background could view it and give there opinions that would be great now that the full text is available online. I could post the whole study but its over 20 pages google the title and see if you can find it.

    by the way... this work was supported in part by NIH grants and a grant from the Basser Research Center awarded to David B. Weiner

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Bump July info for truth

    • No, you're wrong. It has been accepted AND edited. It hasn't been type set or placed into pdf format to be printed. The publisher has to find a place for this and all of the other accepted articles in the journal. Its just basically turning word documents into a magazine is all that is left.

      This is actually pretty awesome news. TERT was recently found to be a major mutation in human melanoma. It was a paper in Science earlier this year entitled: "Highly Recurrent TERT Promoter Mutations in Human Melanoma." Look it up.
      That was huge news. TERT is telomerase. It puts extra DNA at the end of genes. Every time a cell divides, it has to replicate its genome, and each time it replicates its genome, it loses some of that extra DNA. TERT is supposed to be inactivated shortly after you're born, and is theorized to be one of the reasons why we have a limited lifespan... Except in cancer. Cancers reactivate TERT to lengthen their lifespan (just like melanoma).
      But it shouldn't be activated in normal cells, making it a viable cancer target (up in cancer, down in normal cells= targeted therapy.
      In comes Inovio. Is it irony that they are using DNA vaccines get an immune response to a protein (TERT) that manipulates cancer's DNA to live longer?

      This company is definitely going places, and this should get some nice PR.

      Sentiment: Strong Buy

9.44-0.06(-0.63%)Sep 26 4:00 PMEDT